Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Structure Therapeutics

17/04/2025 12:35

Updates

** Shares of drugmaker Eli Lilly LLY.N rise 11.3% to $817.99 premarket

** Company says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial

** U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 3.8%

** Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 4.6% and Amgen AMGN.O down 2%

** Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD

(Reporting by Christy Santhosh in Bengaluru)

((Christy.Santhosh@thomsonreuters.com))